|Proposed EORTC 1999 criteria for clinical and subclinical response assessment by PET-CT|
|Progressive metabolic disease||An increase in 18FDG tumor SUV of greater than 25% within the tumor region defined on the baseline scan, visible increase in the extent of 18FDG tumor uptake (>20% in the longest dimension) or the appearance of new 18FDG uptake in metastatic lesions|
|Stable metabolic disease||An increase in tumor 18FDG SUV of less than 25% or a decrease of less than 15% and no visible increase in extent of 18FDG tumor uptake (>20% in the longest dimension)|
|Partial metabolic response||A reduction of a minimum of 15–25% in tumor 18FDG SUV after one cycle of chemotherapy, and greater than 25% after more than one treatment cycle|
|Complete metabolic response||Complete resolution of 18FDG uptake within the tumor volume so that it was indistinguishable from surrounding normal tissue|
Topkan et al.
Topkan et al. BMC Cancer 2012 12:502 doi:10.1186/1471-2407-12-502